

GLAXOSMITHKLINE PLC  
Form 6-K  
March 18, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington D.C. 20549

**FORM 6-K**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

March 18, 2013

**GlaxoSmithKline plc**

**GlaxoSmithKline Capital plc**  
(Name of registrant)

**GlaxoSmithKline Capital Inc.**  
(Name of registrant)

980 Great West Road, Brentford,

1105 North Market Street, Suite 622,

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

**Middlesex, TW8 9GS**  
(Address of principal executive offices)

**Wilmington, Delaware 19801**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F       Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes       No

THIS REPORT ON FORM 6-K SHALL BE DEEMED TO BE INCORPORATED BY REFERENCE IN THE PROSPECTUS INCLUDED IN THE REGISTRATION STATEMENT ON FORM F-3 (FILE NO. 333-172621) OF GLAXOSMITHKLINE PLC, GLAXOSMITHKLINE CAPITAL PLC AND GLAXOSMITHKLINE CAPITAL INC. AND TO BE A PART THEREOF FROM THE DATE ON WHICH THIS REPORT IS FURNISHED, TO THE EXTENT NOT SUPERSEDED BY DOCUMENTS OR REPORTS SUBSEQUENTLY FILED OR FURNISHED.

## Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

---

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. hereby incorporate by reference the following exhibits to this report on Form 6-K into their Registration Statement on Form F-3 (File Nos. 333-172621, 333-172621-01, 333-172621-02).

Exhibit No.	Description of Document
1.1	Underwriting Agreement, dated as of March 13, 2013, among GlaxoSmithKline Capital Inc., GlaxoSmithKline plc, Deutsche Bank Securities Inc., Goldman, Sachs & Co., J.P. Morgan Securities LLC and UBS Securities LLC, as representatives of the several underwriters named therein.
4.1	First Supplemental Indenture, dated as of March 18, 2013, among GlaxoSmithKline Capital Inc., GlaxoSmithKline plc and Law Debenture Trust Company of New York.
5.1	Opinion of Cleary Gottlieb Steen & Hamilton LLP, special U.S. counsel to GlaxoSmithKline plc and GlaxoSmithKline Capital Inc.
5.2	Opinion of Cleary Gottlieb Steen & Hamilton LLP, special English counsel to GlaxoSmithKline plc and GlaxoSmithKline Capital Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
**GlaxoSmithKline Capital plc and**  
**GlaxoSmithKline Capital Inc.**  
(Registrants)

Date: March 18, 2013

By: /s/ Victoria Whyte

Victoria Whyte  
Authorised Signatory for and on behalf of  
GlaxoSmithKline plc  
GlaxoSmithKline Capital plc and  
GlaxoSmithKline Capital Inc.